Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
James Croft
Institutions:
Institute of Cancer Research,
Royal Marsden Hospital
Observed institutions:
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
St Helier Hospital,
Epsom and St Helier University Hospitals NHS Trust,
Eastbourne District General Hospital,
Royal Marsden Hospital
show all 6
ORCID:
0000-0002-3782-6928
Observed ORCID:
0000-0002-3782-6928
OpenAlex ID:
A5013749352
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma
2021
·
Christina Messiou
, Nuria Porta
, et al.
·
Radiology Imaging Cancer
·
66
PDF
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
2020
·
James Croft
, Sidra Ellis
, et al.
·
Leukemia
·
46
PDF
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
2021
·
Kwee L. Yong
, Samantha Hinsley
, et al.
·
Haematologica
·
20
PDF
Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma
2025
·
Christina Messiou
, Nuria Porta
, et al.
·
Blood Cancer Journal
·
16
PDF
Inter-observer agreement of baseline whole body MRI in multiple myeloma
2020
·
James Croft
, Angela Riddell
, et al.
·
Cancer Imaging
·
11
PDF
Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone
2018
·
James Croft
, Andrew Hall
, et al.
·
Blood
·
8
Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment
2020
·
Martin F. Kaiser
, James Croft
, et al.
·
British Journal of Haematology
·
7
PDF
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial
2019
·
James Croft
, Andrew Hall
, et al.
·
Blood
·
6
Acquired haemophilia A in hepatocellular carcinoma
2013
·
James Croft
, Satyajit Sahu
·
British Journal of Haematology
·
6
Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
2019
·
Matthew Jenner
, Amy L Sherborne
, et al.
·
Blood
·
3
Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial
2018
·
James Croft
, Andrew Hall
, et al.
·
Blood
·
3
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
2025
·
Giuseppe Bertuglia
, Elisa Seneca
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial
2026
·
Andrew Hall
, James Croft
, et al.
·
British Journal of Haematology
·
1
Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma
2018
·
Priya Sriskandarajah
, Kevin Boyd
, et al.
·
Blood
·
1
Outcomes following Treatment with Bortezomib in Patients with Multiple Myeloma Who Required Haemodialysis: A Single-Centre Experience
2024
·
Mohammad Rabiul Islam Rony
, Omaisa Mushtaq
, et al.
·
Journal of the American Society of Nephrology
OAB-060: Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: results of the iTIMM trial
2021
·
Martin Kaiser
, Nuria Porta
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial
2017
·
Amy L. Sherborne
, Vallari Shah
, et al.
·
Blood
Show more works
View as search
Works count:
17
Citation count:
196
H-index:
7
I10-index:
5
Year
Topic
Type